aTyr Pharma
ATYR
56 hedge funds and large institutions have $81.5M invested in aTyr Pharma in 2024 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 21 increasing their positions, 10 reducing their positions, and 4 closing their positions.
275% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 4
110% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 10
88% more call options, than puts
Call options by funds: $15K | Put options by funds: $8K
40% more capital invested
Capital invested by funds: $58.1M → $81.5M (+$23.4M)
24% more funds holding
Funds holding: 45 → 56 (+11)
8.67% less ownership
Funds ownership: 70.38% → 61.71% (-8.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$2.93M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$1.22M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$1.05M |
| 4 |
Barclays
London,
United Kingdom
|
+$916K |
| 5 |
Renaissance Technologies
New York
|
+$689K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$4.8M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.66M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$680K |
| 4 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
-$353K |
| 5 |
Squarepoint
New York
|
-$168K |
ATYR Hedge Fund Activity: Q1 2024 in Review
56 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q1 2024, worth a combined $81.5M — up 40% from $58.1M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ATYR positions and 4 closed out — a net gain of 11 holders — while 21 added to existing stakes and 10 trimmed.
The largest buyer was Woodline Partners, opening a new position worth an estimated $2.93M. The largest seller was Logos Global Management, cutting an estimated $4.8M.
- 56 institutional investors held aTyr Pharma (ATYR) as of Q1 2024, up from 45 in Q4 2023.
- Funds reported $81.5M of aTyr Pharma stock for Q1 2024, up 40% quarter-over-quarter.
- 15 funds opened new aTyr Pharma positions in Q1 2024 and 4 closed out, a net change of +11 holders.
- The largest aTyr Pharma buyer in Q1 2024 was Woodline Partners, an estimated $2.93M added.
- The largest aTyr Pharma seller in Q1 2024 was Logos Global Management, an estimated $4.8M sold.
Based on aggregated 13F filings for Q1 2024.